Zevra Therapeutics (ZVRA) Competitors

ANI Pharmaceuticals (NASDAQ:ANIP) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, community ranking, analyst recommendations, dividends, media sentiment and earnings.

Do analysts recommend ANIP or ZVRA?

ANI Pharmaceuticals currently has a consensus target price of $79.75, suggesting a potential upside of 15.25%. Zevra Therapeutics has a consensus target price of $22.29, suggesting a potential upside of 216.11%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Zevra Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Zevra Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11

Which has better valuation & earnings, ANIP or ZVRA?

ANI Pharmaceuticals has higher revenue and earnings than Zevra Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$614.38M	2.45	$18.78M	-$1.14	-60.70
Zevra Therapeutics	$23.61M	16.16	-$46.05M	-$2.24	-3.15

Which has more risk and volatility, ANIP or ZVRA?

ANI Pharmaceuticals has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.94, indicating that its stock price is 94% more volatile than the S&P 500.

Is ANIP or ZVRA more profitable?

ANI Pharmaceuticals has a net margin of -1.28% compared to Zevra Therapeutics' net margin of -342.63%. ANI Pharmaceuticals' return on equity of 15.87% beat Zevra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	-1.28%	15.87%	6.88%
Zevra Therapeutics	-342.63%	-159.54%	-51.50%

Does the media favor ANIP or ZVRA?

In the previous week, ANI Pharmaceuticals had 21 more articles in the media than Zevra Therapeutics. MarketBeat recorded 21 mentions for ANI Pharmaceuticals and 0 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.93 beat ANI Pharmaceuticals' score of 0.93 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
ANI Pharmaceuticals	Positive
Zevra Therapeutics	Positive

Does the MarketBeat Community believe in ANIP or ZVRA?

ANI Pharmaceuticals received 404 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 94.74% of users gave Zevra Therapeutics an outperform vote while only 64.42% of users gave ANI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
ANI Pharmaceuticals	Outperform Votes 440 64.42%	Underperform Votes 243 35.58%
Zevra Therapeutics	Outperform Votes 36 94.74%	Underperform Votes 2 5.26%

Do insiders & institutionals believe in ANIP or ZVRA?

76.1% of ANI Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are owned by institutional investors. 12.7% of ANI Pharmaceuticals shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

ANI Pharmaceuticals beats Zevra Therapeutics on 10 of the 18 factors compared between the two stocks.